{"transactions":[{"id":4638047,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":83060,"kind":"person","name":"Uden Stephen","position":1,"cik":"0001332141","reported_name":"Uden Stephen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (Right to Buy)","published_at":"2026-10-08T21:04:44.000Z","date":"2026-10-06","kind":"exercise","planned":false,"acquired":false,"shares":22456,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is granted under the Company's 2021 Equity Incentive Plan. The option vests in 48 equal monthly installments until fully vested on February 14, 2029."}],"balance_after":0,"derivative":{"exercise_price":6.08,"expiration_date":"2035-02-14","underlying":"Common Stock","underlying_shares":22456},"source":{"system":"sec-edgar","filing":"0001193125-26-418051","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000119312526418051/ownership.xml","form_type":"4"}},{"id":4638046,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":83060,"kind":"person","name":"Uden Stephen","position":1,"cik":"0001332141","reported_name":"Uden Stephen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-08T21:04:44.000Z","date":"2026-10-06","kind":"exercise","planned":false,"acquired":true,"shares":22456,"price":6.08,"value":136532.48,"ownership":{"direct":true},"balance_after":115620,"source":{"system":"sec-edgar","filing":"0001193125-26-418051","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000119312526418051/ownership.xml","form_type":"4"}},{"id":1260091,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":83060,"kind":"person","name":"Uden Stephen","position":1,"cik":"0001332141","reported_name":"Uden Stephen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (Right to Buy)","published_at":"2025-02-20T00:30:54.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":453700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is granted under the Company's 2021 Equity Incentive Plan. The option vests in 48 equal monthly installments until fully vested on February 14, 2029."}],"balance_after":453700,"derivative":{"exercise_price":0.76,"expiration_date":"2035-02-14","underlying":"Common Stock","underlying_shares":453700},"source":{"system":"sec-edgar","filing":"0001739410-25-000014","document":"wk-form4_1740011448.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941025000014/wk-form4_1740011448.xml","form_type":"4"}},{"id":1638343,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":83060,"kind":"person","name":"Uden Stephen","position":1,"cik":"0001332141","reported_name":"Uden Stephen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (Right to Buy)","published_at":"2024-02-16T23:22:25.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":216000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is granted under the Company's 2021 Equity Incentive Plan.  The option vests in 48 equal monthly installments until fully vested on February 15, 2028."}],"balance_after":216000,"derivative":{"exercise_price":1.86,"expiration_date":"2034-02-15","underlying":"Common Stock","underlying_shares":216000},"source":{"system":"sec-edgar","filing":"0001739410-24-000020","document":"wk-form4_1708125735.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000020/wk-form4_1708125735.xml","form_type":"4"}},{"id":2030652,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":83060,"kind":"person","name":"Uden Stephen","position":1,"cik":"0001332141","reported_name":"Uden Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Option (Right to Buy)","published_at":"2023-02-06T22:42:58.000Z","date":"2023-02-06","kind":"grant","acquired":true,"shares":214000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is granted under the Company's 2021 Equity Incentive Plan.  The option vests in 48 equal monthly installments until fully vested on February 6, 2027."}],"balance_after":214000,"derivative":{"exercise_price":6.5,"expiration_date":"2033-02-06","underlying":"Common Stock","underlying_shares":214000},"source":{"system":"sec-edgar","filing":"0000899243-23-004078","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924323004078/doc4.xml","form_type":"4"}},{"id":2406500,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":83060,"kind":"person","name":"Uden Stephen","position":1,"cik":"0001332141","reported_name":"Uden Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Option (Right to Buy)","published_at":"2022-02-10T00:39:34.000Z","date":"2022-02-07","kind":"grant","acquired":true,"shares":62000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is granted under the Company's 2021 Equity Incentive Plan.  The option vests in 48 equal monthly installments until fully vested on February 7, 2026."}],"balance_after":62000,"derivative":{"exercise_price":15.04,"expiration_date":"2032-02-07","underlying":"Common Stock","underlying_shares":62000},"source":{"system":"sec-edgar","filing":"0000899243-22-005521","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322005521/doc4.xml","form_type":"4"}},{"id":2434998,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":83060,"kind":"person","name":"Uden Stephen","position":1,"cik":"0001332141","reported_name":"Uden Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Option (Right to Buy)","published_at":"2022-01-15T01:11:07.000Z","date":"2021-07-28","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests as to 25% of the underlying shares of Common Stock on July 28, 2022 and as to the remaining 75% of the underlying shares of Common Stock in 36 equal monthly installments thereafter."}],"balance_after":160000,"derivative":{"exercise_price":13,"expiration_date":"2031-07-28","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0000899243-22-002043","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322002043/doc4.xml","form_type":"4"}},{"id":2434997,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":83060,"kind":"person","name":"Uden Stephen","position":1,"cik":"0001332141","reported_name":"Uden Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Series B Preferred Units","published_at":"2022-01-15T01:11:07.000Z","date":"2021-07-28","kind":"other","acquired":false,"shares":107891,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":16944},"source":{"system":"sec-edgar","filing":"0000899243-22-002043","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322002043/doc4.xml","form_type":"4"}},{"id":2434996,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":83060,"kind":"person","name":"Uden Stephen","position":1,"cik":"0001332141","reported_name":"Uden Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Series A-2 Preferred Units","published_at":"2022-01-15T01:11:07.000Z","date":"2021-07-28","kind":"other","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15704},"source":{"system":"sec-edgar","filing":"0000899243-22-002043","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322002043/doc4.xml","form_type":"4"}},{"id":2434995,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":83060,"kind":"person","name":"Uden Stephen","position":1,"cik":"0001332141","reported_name":"Uden Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Series A-1 Preferred Units","published_at":"2022-01-15T01:11:07.000Z","date":"2021-07-28","kind":"other","acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":23557},"source":{"system":"sec-edgar","filing":"0000899243-22-002043","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322002043/doc4.xml","form_type":"4"}},{"id":2434994,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":83060,"kind":"person","name":"Uden Stephen","position":1,"cik":"0001332141","reported_name":"Uden Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common  Units","published_at":"2022-01-15T01:11:07.000Z","date":"2021-07-28","kind":"other","acquired":false,"shares":4820000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":652922},"source":{"system":"sec-edgar","filing":"0000899243-22-002043","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322002043/doc4.xml","form_type":"4"}},{"id":2434993,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":83060,"kind":"person","name":"Uden Stephen","position":1,"cik":"0001332141","reported_name":"Uden Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-01-15T01:11:07.000Z","date":"2022-01-13","kind":"purchase","acquired":true,"shares":807,"price":9.62,"value":7763.34,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.29 to $10.28, inclusive."}],"balance_after":719127,"source":{"system":"sec-edgar","filing":"0000899243-22-002043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322002043/doc4.xml","form_type":"4"}},{"id":2434992,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":83060,"kind":"person","name":"Uden Stephen","position":1,"cik":"0001332141","reported_name":"Uden Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-01-15T01:11:07.000Z","date":"2022-01-13","kind":"purchase","acquired":true,"shares":4193,"price":9.06,"value":37988.58,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.29 to $9.28, inclusive."}],"balance_after":718320,"source":{"system":"sec-edgar","filing":"0000899243-22-002043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322002043/doc4.xml","form_type":"4"}},{"id":2434991,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":83060,"kind":"person","name":"Uden Stephen","position":1,"cik":"0001332141","reported_name":"Uden Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-01-15T01:11:07.000Z","date":"2022-01-12","kind":"purchase","acquired":true,"shares":5000,"price":10.55,"value":52750.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.01 to $11.00, inclusive. The reporting person undertakes to provide to Rallybio Corporation, any security holder of Rallybio Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4."}],"balance_after":714127,"source":{"system":"sec-edgar","filing":"0000899243-22-002043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322002043/doc4.xml","form_type":"4"}},{"id":2434990,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":83060,"kind":"person","name":"Uden Stephen","position":1,"cik":"0001332141","reported_name":"Uden Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-01-15T01:11:07.000Z","date":"2021-07-28","kind":"other","acquired":true,"shares":709127,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."}],"balance_after":709127,"source":{"system":"sec-edgar","filing":"0000899243-22-002043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322002043/doc4.xml","form_type":"4"}}]}